Tirzepatide Purification by Xtimate C8
Tirzepatide is a medication that acts simultaneously on GIP and GLP-1. In May 2022, Tirzepatide received FDA approval for marketing and was used for the treatment of diabetes, while also obtaining fast-track qualification for obesity.
On November 8, 2023, Eli Lilly announced that the FDA had approved their Zepbound (Tirzepatide) injection, marking the official entry of Eli Lilly's Tirzepatide into the chronic weight management market.
This is the first and only medication for obesity treatment that acts as a dual agonist of glucose-dependent insulinotropic peptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.
Sharing the Purification Processes for Two Batches of Tirzepatide Active Pharmaceutical Ingredients with Different Purity Levels
Case One - Crude Peptide purity 74.95%
Purification Process as follows:
Primary Purification
Chromatography Packing Material: Xtimate® C8, 10μm, 120Å
Results: After primary purification, purity reached 92.44%, with a recovery rate of 75%. The loading volume was 0.5% of the Packing Materials volume.
Secondary Purification
Chromatography Packing Material: Xtimate® C8, 10μm, 120Å
Results: After secondary purification, purity reached 99.21%, with a recovery rate of 50%. The loading volume was 0.4% of the Packing Materials volume.
Case Two - Crude Peptide purity 41.11%
Purification Process as follows:
Primary Purification
Chromatography Packing Material: Xtimate® C8, 10μm, 120Å
Results: After purification, the purity reached 79.63%, with a recovery rate of 50%. The loading volume was 0.2% of the Packing Materials volume.
Secondary Purification
Chromatography Packing Material: Xtimate® C8, 10μm, 120Å
Results: After purification, the purity reached 99.95%, with a recovery rate of 60%. The loading volume was 0.1% of the Packing Material volume.
Summary:
Product information: